Anna Niwińska1, Magdalena Murawska. 1. Department of Breast Cancer and Reconstructive Surgery, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. alphaonetau@poczta.onet.pl
Abstract
PURPOSE: The aim of the study was to present a new breast cancer recursive partitioning analysis (RPA) prognostic index for patients with newly diagnosed brain metastases as a guide in clinical decision making. METHODS AND MATERIALS: A prospectively collected group of 441 consecutive patients with breast cancer and brain metastases treated between the years 2003 and 2009 was assessed. Prognostic factors significant for univariate analysis were included into RPA. RESULTS: Three prognostic classes of a new breast cancer RPA prognostic index were selected. The median survival of patients within prognostic Classes I, II, and III was 29, 9, and 2.4 months, respectively (p < 0.0001). Class I included patients with one or two brain metastases, without extracranial disease or with controlled extracranial disease, and with Karnofsky performance status (KPS) of 100. Class III included patients with multiple brain metastases with KPS of ≤60. Class II included all other cases. CONCLUSIONS: The breast cancer RPA prognostic index is an easy and valuable tool for use in clinical practice. It can select patients who require aggressive treatment and those in whom whole-brain radiotherapy or symptomatic therapy is the most reasonable option. An individual approach is required for patients from prognostic Class II. Copyright Â
PURPOSE: The aim of the study was to present a new breast cancer recursive partitioning analysis (RPA) prognostic index for patients with newly diagnosed brain metastases as a guide in clinical decision making. METHODS AND MATERIALS: A prospectively collected group of 441 consecutive patients with breast cancer and brain metastases treated between the years 2003 and 2009 was assessed. Prognostic factors significant for univariate analysis were included into RPA. RESULTS: Three prognostic classes of a new breast cancer RPA prognostic index were selected. The median survival of patients within prognostic Classes I, II, and III was 29, 9, and 2.4 months, respectively (p < 0.0001). Class I included patients with one or two brain metastases, without extracranial disease or with controlled extracranial disease, and with Karnofsky performance status (KPS) of 100. Class III included patients with multiple brain metastases with KPS of ≤60. Class II included all other cases. CONCLUSIONS: The breast cancer RPA prognostic index is an easy and valuable tool for use in clinical practice. It can select patients who require aggressive treatment and those in whom whole-brain radiotherapy or symptomatic therapy is the most reasonable option. An individual approach is required for patients from prognostic Class II. Copyright Â
Authors: Kaisorn L Chaichana; Shekhar Gadkaree; Karthik Rao; Thomas Link; Daniele Rigamonti; Michael Purtell; Ilene Browner; Jon Weingart; Alessandro Olivi; Gary Gallia; Chetan Bettegowda; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa Journal: Neurol Res Date: 2013-08-16 Impact factor: 2.448
Authors: Ishwaria M Subbiah; Xiudong Lei; Jeffrey S Weinberg; Erik P Sulman; Mariana Chavez-MacGregor; Debu Tripathy; Rohan Gupta; Ankur Varma; Jay Chouhan; Richard P Guevarra; Vicente Valero; Mark R Gilbert; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2015-05-18 Impact factor: 44.544
Authors: Markus Kuksis; Yizhuo Gao; William Tran; Christianne Hoey; Alex Kiss; Adam S Komorowski; Aman J Dhaliwal; Arjun Sahgal; Sunit Das; Kelvin K Chan; Katarzyna J Jerzak Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300